Business
Longeveron Announces Key Additions To Its Leadership Team and Board As It Gears Up For Phase 2 Trials For Its Lead Drug Candidate For Several Conditions
--News Direct--By David Willey, BenzingaLongeveron, Inc. (NASDAQ: LGVN) is a clinical-stage biopharmaceutical company focused on therapies for age-related and
About this update from Longeveron Inc.
[{"type":"text","content":"--News Direct--By David Willey, BenzingaLongeveron, Inc. (NASDAQ: LGVN) is a clinical-stage biopharmaceutical company focused on therapies for age-related and life-threatening diseases. Longeveron’s primary drug is Lomecel-B™, which is being developed as a potential therapy for Alzheimer's disease, Aging-Frailty, and a rare pediatric disease, hypoplastic left heart syndrome (HLHS).After almost a decade of research and development (R&D) and collecting safety and efficacy data, the Company is initiating additional phase 2 trials for Lomecel-B™ as a potential treatment for these indications. To help the Company with its continued growth and development, the Company has brought on additional experienced leaders to its board and leadership team. These leaders bring a wealth of expertise in drug development, regulatory filing and product commercialization.Longeveron believes that its recent appointments should inspire even greater confidence in its investors as the Company advances its trials for Lomecel-B™.CEO And Board Member Appointments In March 2023, Longeveron appointed Wa’el Hashad as its new Chief Executive Officer (CEO). Hashad brings over three decades of experience in global pharmaceutical and biotechnology companies like Amgen (NASDAQ: AMGN) and Eli Lilly and Company (NYSE: LLY), and he has been involved in drug development, mergers and acquisitions and product commercialization. Before joining Longeveron, Hashad spent six years as CEO of Avanir Pharmaceuticals, where he oversaw the company’s integration with Otsuka.“I am honored to join Longeveron as CEO,” said Hashad. “With its robust clinical pipeline, Longeveron is well-positioned as a leader in regenerative medicines. I look forward to working with the Board, management, and the broader Longeveron team to continue the impressive progress to date and advance Lomecel-B™ as a potential therapy across multiple disease areas.” Hashad was recently appointed to Longeveron’s Board of Directors, along with prominent biotechnology and corporate management experts Khoso Baluch and Jeffrey Pfeffer. Baluch has 36 years of experience in the biopharmaceutical industry and has held positions at multiple companies including Eli Lilly and CorMedix Inc. and is currently chairman of the board for Poxel SA. Pfeffer also brings extensive management experience to Longeveron as a current and...